[Public clinical trials: which kind of monitoring should be used?].

Date publication

mai 2013

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BINQUET Christine

Tous les auteurs :
Cornu C, Binquet C, Thalamas C, Vigouroux C, Gaillard S, Ginhoux T, Vaz B, Jossan C, Felin A, Sailly A, Gueyffier F, Journot V, Kassai B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/23886457

Résumé

OBJECTIVE: Sponsors must take responsibility for the quality of trials at the best possible cost. Our objective was to describe the most frequent quality failures, how they impact trial results, and identify the most efficient monitoring strategies using published articles and reports. RESULTS: Errors affecting clinical trials include conception, procedures, data management, and data analysis. The consequences are usually an overestimation of the treatment effect. No study shows that monitoring reduces the risk of errors, and there is no comparison of monitoring methods. Many research organisations advocate for monitoring based on risk analysis and recommend an extensive use of centralised monitoring. CONCLUSIONS: Trial quality depends on trial conception and design. Study conduct should guarantee a maximum level of quality level. This should be done using risk management and extensive centralised monitoring.

Référence

Therapie. 2013 May-Jun;68(3):135-41